Rocket


News + Filings
Transactions





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other



BIZZARI JEAN-PIERRE Create: Alert

All | News | Filings
Date FiledTypeDescription
08/24/2023 4 BIZZARI JEAN-PIERRE (Director) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns: Granted 12,500 options to buy @ $3.65, valued at $45.6k
08/24/2023 3 BIZZARI JEAN-PIERRE (Director) has filed a Form 3 on Aprea Therapeutics, Inc.
05/09/2023 4 BIZZARI JEAN-PIERRE (Director) has filed a Form 4 on HALOZYME THERAPEUTICS, INC.
Txns: Granted 8,065 shares @ $0
Granted 11,371 options to buy @ $31, valued at $352.5k
05/06/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/25/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
05/06/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
05/01/2020 4 BIZZARI JEAN-PIERRE (Director) has filed a Form 4 on HALOZYME THERAPEUTICS, INC.
Txns: Granted 8,829 shares @ $0
01/28/2020 4 BIZZARI JEAN-PIERRE (Director) has filed a Form 4 on PIERIS PHARMACEUTICALS, INC.
Txns: Granted 20,000 options to buy @ $3.23, valued at $64.6k
05/03/2019 4 BIZZARI JEAN-PIERRE (Director) has filed a Form 4 on HALOZYME THERAPEUTICS INC
Txns: Granted 12,173 shares @ $0
01/29/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
05/02/2018 4 BIZZARI JEAN-PIERRE (Director) has filed a Form 4 on HALOZYME THERAPEUTICS INC
Txns: Granted 10,363 shares @ $0
05/05/2017 4 Form 4 - Statement of changes in beneficial ownership of securities
01/30/2017 4 BIZZARI JEAN-PIERRE (Director) has filed a Form 4 on PIERIS PHARMACEUTICALS, INC.
Txns: Granted 20,000 options to buy @ $2.01, valued at $40.2k
07/12/2016 4 Form 4 - Statement of changes in beneficial ownership of securities
05/06/2016 4 BIZZARI JEAN-PIERRE (Director) has filed a Form 4 on HALOZYME THERAPEUTICS INC
Txns: Granted 20,202 shares @ $0
02/18/2016 4 Form 4 - Statement of changes in beneficial ownership of securities

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy